Statins and cancer [4]

Epidemiology

Volumn 18, Issue 4, 2007, Pages 520-

  Duncan, Robin E ^a   El Sohemy, Ahmed ^b   Archer, Michael C ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; PRAVASTATIN;

CANCER; CANCER RISK; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; LETTER; LIPOPHILICITY; NONHUMAN; PRIORITY JOURNAL; PROTECTION; TUMOR GROWTH; METABOLISM; NEOPLASM; NOTE; RISK;

CASE-CONTROL STUDIES; HUMANS; HYDROPHOBICITY; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEOPLASMS; ODDS RATIO; PRAVASTATIN; RISK;

EID: 34250693757     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/EDE.0b013e3180646707     Document Type: Letter

References (3)

1. Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. Epidemiology. 2007;18:213-219.
2. Duncan RE, El-Sohemy A, Archer MC. Statins and cancer development. Cancer Epidemiol Biomarkers Prev. 2005;14:1897-1898.
3. Duncan RE, El-Sohemy A, Archer MC. Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity. J Biol Chem. 2004;279:33079-33084.